S Maltoni1, A Messori. 1. Laboratorio SIFO di Farmacoeconomia, Careggi Hospital, Florence, Italy.
Abstract
OBJECTIVE: To evaluate the cost-effectiveness profile of topiramate as adjunctive treatment in patients with refractory epilepsy. STUDY DESIGN: Lifetime cost-utility analysis based on a pharmacoeconomic model. METHODS: Effectiveness data (seizure frequency reduction) were derived from the most recent placebo-controlled clinical trial, whilst quality of life and cost data were retrieved from the published literature. Our pharmacoeconomic model was based on a patient-level approach that incorporated the clinical data of the randomised, controlled trial. MAIN OUTCOME MEASURES AND RESULTS: Our analysis showed that chronic topiramate treatment costs pound21 353 per quality-adjusted life year (QALY) gained (incremental lifetime cost of pound1 024 941 and incremental utility of 48 QALYs, for every 100 patients) [discounted values with a yearly rate of 3%] (year of costing 2001). Sensitivity analyses suggested a range from pound19 915 to pound24 518 per QALY gained. CONCLUSIONS: Our results showed that adjunctive topiramate therapy has a favourable pharmacoeconomic profile in patients with refractory epilepsy.
RCT Entities:
OBJECTIVE: To evaluate the cost-effectiveness profile of topiramate as adjunctive treatment in patients with refractory epilepsy. STUDY DESIGN: Lifetime cost-utility analysis based on a pharmacoeconomic model. METHODS: Effectiveness data (seizure frequency reduction) were derived from the most recent placebo-controlled clinical trial, whilst quality of life and cost data were retrieved from the published literature. Our pharmacoeconomic model was based on a patient-level approach that incorporated the clinical data of the randomised, controlled trial. MAIN OUTCOME MEASURES AND RESULTS: Our analysis showed that chronic topiramate treatment costs pound21 353 per quality-adjusted life year (QALY) gained (incremental lifetime cost of pound1 024 941 and incremental utility of 48 QALYs, for every 100 patients) [discounted values with a yearly rate of 3%] (year of costing 2001). Sensitivity analyses suggested a range from pound19 915 to pound24 518 per QALY gained. CONCLUSIONS: Our results showed that adjunctive topiramate therapy has a favourable pharmacoeconomic profile in patients with refractory epilepsy.
Authors: D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson Journal: N Engl J Med Date: 1995-05-25 Impact factor: 91.245
Authors: Hoi Yau Chan; Ben F M Wijnen; Marian H J M Majoie; Silvia M A A Evers; Mickaël Hiligsmann Journal: Epilepsia Date: 2021-12-30 Impact factor: 6.740